Series A financing

Pfizer, OrbiMed, Sofinnova Ventures, Canaan Partners and Lilly Asia Ventures

Our attorneys advised a consortium of institutional investors comprising longtime client Pfizer Inc., OrbiMed, Sofinnova Ventures, Canaan Partners, and Lilly Asia Ventures in a Series A financing of newly formed biopharmaceutical company NextCure Inc. of up to $67 million. The first closing of the financing, consisting of an initial $15 million investment, occurred on December 29, 2015.

Launched by Dr. Lieping Chen and Michael Richman in 2015, NextCure is focused on the development of immuno-oncology targeted gene-therapies in collaboration with Yale University. The company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.

Email Disclaimer